AlphaCrest Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AlphaCrest Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,982	Closed	-$232K	–	1196
2022 Q3	$232K	Sell	4,982 -5,253	-51%	-$274K	0.01%	1211
2022 Q2	$584K	Buy	+10,235	New	+$580K	0.03%	898
2022 Q1	–	Sell	-4,600	Closed	-$241K	–	1436
2021 Q4	$241K	Buy	+4,600	New	+$193K	0.01%	1301
2021 Q3	–	Sell	-5,200	Closed	-$212K	–	1404
2021 Q2	$212K	Buy	+5,200	New	+$192K	0.01%	1186
2021 Q1	–	Sell	-8,300	Closed	-$264K	–	1334
2020 Q4	$264K	Buy	+8,300	New	+$218K	0.02%	963

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AlphaCrest Capital Management's ITCI Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 4,982 shares — an estimated $232K sold.

AlphaCrest Capital Management first reported a position in ITCI in Q4 2020 and held it in 5 quarters. The position peaked at $584K in Q2 2022. 283 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

AlphaCrest Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 4,982 Intra-Cellular Therapies Inc. shares in Q4 2022, an estimated $232K.
AlphaCrest Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 5 quarters.
AlphaCrest Capital Management's Intra-Cellular Therapies Inc. position peaked at $584K in Q2 2022.
283 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.